Transcription factor activity and inferred myeloid-CD8 signaling by pathological response in lung adenocarcinoma and squamous cell carcinoma after neoadjuvant PD-1 therapy

Patients with resectable non-small cell lung cancer differ widely in the depth of their pathological response to neoadjuvant anti-PD-1 plus chemotherapy, and what distinguishes tumors with a major pathological response (MPR) from those without is incompletely defined. We analyzed a published single-cell dataset of CD45+ cells from 234 patients. After excluding complete pathological responders, MPR and non-MPR tumors were compared separately in adenocarcinoma and squamous carcinoma. Exhausted CD8 T cells (CD8.TEX) and tumor-associated macrophages (TAMs) were characterized by composition and functional state, transcription factor activity, and cell-cell communication. In CD8.TEX cells, cytotoxicity and exhaustion scores were significantly higher in non-MPR tumors in both histologies. The proportion of CD8.TEX cells was significantly higher in non-MPR tumors in squamous carcinoma but not in adenocarcinoma. Transcription factor activity differed significantly in adenocarcinoma (12 of 479 factors, 10 more active in non-MPR tumors and 2 in MPR tumors) but none of the 461 factors tested in squamous carcinoma did. In squamous carcinoma, 258 genes were differentially expressed in CD8.TEX cells, and 145 of them (56%) have no documented regulator in the network used (24 of 65, 37%, in adenocarcinoma). In the myeloid compartment, the proportions of macrophages and monocytes did not differ significantly between response groups, whereas transcription factor activity did, mostly higher in non-MPR tumors (adenocarcinoma: 68 of 70 factors in macrophages and 35 of 36 in monocytes; squamous carcinoma: 7 of 8 and 9 of 13). Nine ligand-receptor axes described in the literature (four immunosuppressive, two anti-tumor and three context-dependent) were found among the interactions prioritized for CD8.TEX cells. In non-MPR tumors, all nine were found in adenocarcinoma and eight in squamous carcinoma, against one and two, respectively, in MPR tumors. In this cohort, the differences between MPR and non-MPR tumors lay mostly on the non-MPR side, both in transcription factor activity and in the literature axes found among the prioritized interactions.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24423379
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Transcription factor activity and inferred myeloid-CD8 signaling by pathological response in lung adenocarcinoma and squamous cell carcinoma after neoadjuvant PD-1 therapy

Myriam Yasmina Soumahoro
Zenodo (CERN European Organization for Nuclear Research)
Cancer Immunotherapy and Biomarkers
preprint

Transcription factor activity and inferred myeloid-CD8 signaling by pathological response in lung adenocarcinoma and squamous cell carcinoma after neoadjuvant PD-1 therapy

Myriam Yasmina Soumahoro
preprint en

Abstract

Patients with resectable non-small cell lung cancer differ widely in the depth of their pathological response to neoadjuvant anti-PD-1 plus chemotherapy, and what distinguishes tumors with a major pathological response (MPR) from those without is incompletely defined. We analyzed a published single-cell dataset of CD45+ cells from 234 patients. After excluding complete pathological responders, MPR and non-MPR tumors were compared separately in adenocarcinoma and squamous carcinoma. Exhausted CD8 T cells (CD8.TEX) and tumor-associated macrophages (TAMs) were characterized by composition and functional state, transcription factor activity, and cell-cell communication. In CD8.TEX cells, cytotoxicity and exhaustion scores were significantly higher in non-MPR tumors in both histologies. The proportion of CD8.TEX cells was significantly higher in non-MPR tumors in squamous carcinoma but not in adenocarcinoma. Transcription factor activity differed significantly in adenocarcinoma (12 of 479 factors, 10 more active in non-MPR tumors and 2 in MPR tumors) but none of the 461 factors tested in squamous carcinoma did. In squamous carcinoma, 258 genes were differentially expressed in CD8.TEX cells, and 145 of them (56%) have no documented regulator in the network used (24 of 65, 37%, in adenocarcinoma). In the myeloid compartment, the proportions of macrophages and monocytes did not differ significantly between response groups, whereas transcription factor activity did, mostly higher in non-MPR tumors (adenocarcinoma: 68 of 70 factors in macrophages and 35 of 36 in monocytes; squamous carcinoma: 7 of 8 and 9 of 13). Nine ligand-receptor axes described in the literature (four immunosuppressive, two anti-tumor and three context-dependent) were found among the interactions prioritized for CD8.TEX cells. In non-MPR tumors, all nine were found in adenocarcinoma and eight in squamous carcinoma, against one and two, respectively, in MPR tumors. In this cohort, the differences between MPR and non-MPR tumors lay mostly on the non-MPR side, both in transcription factor activity and in the literature axes found among the prioritized interactions.

Zenodo (CERN European Organization for Nuclear Research)
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Transcription factor activity and inferred myeloid-CD8 signaling by pathological response in lung adenocarcinoma and squamous cell carcinoma after neoadjuvant PD-1 therapy — Myriam Yasmina Soumahoro · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS